Skip to main content
Top
Published in: American Journal of Cardiovascular Drugs 3/2003

01-05-2003 | Leading Article

Risk of Suicide in Users of Cardiovascular Drugs

A Review of the Epidemiological Evidence

Authors: Dr Peter Jepsen, Søren P. Johnsen, Henrik T. Sørensen

Published in: American Journal of Cardiovascular Drugs | Issue 3/2003

Login to get access

Abstract

An association between consumption of cardiovascular drugs and increased risk of depression was first reported more than 30 years ago. More recently three observational studies have also reported an association between the use of cardiovascular drugs and risk of suicide. We review the epidemiological evidence with particular focus on bias, confounding, and chance as alternative explanations to a causal association. The results of the three studies are inconsistent with respect to the association between cardiovascular drug use and suicide. None of the studies has been able to control fully for possible confounding, in particular by the underlying disease and comorbidity.
We thus conclude that the finding of an association between suicide risk and cardiovascular drug use remains dubious. A true explanation for the apparent increase in risk of suicide in users of cardiovascular drugs remains unknown. Future studies must try to reduce confounding. Meta-analyses of data from existing trials may be an approach to solve the problem of confounding.
Literature
2.
go back to reference Avorn J, Everitt DE, Weiss S. Increased antidepressant use in patients prescribed beta-blockers. JAMA 1986 Jan 17; 255(3): 357–60PubMedCrossRef Avorn J, Everitt DE, Weiss S. Increased antidepressant use in patients prescribed beta-blockers. JAMA 1986 Jan 17; 255(3): 357–60PubMedCrossRef
3.
go back to reference Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology 1996 Sep; 7(5): 478–84PubMedCrossRef Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology 1996 Sep; 7(5): 478–84PubMedCrossRef
4.
go back to reference Patten SB. Propranolol and depression: evidence from the antihypertensive trials. Can J Psychiatry 1990 Apr; 35(3): 257–9PubMed Patten SB. Propranolol and depression: evidence from the antihypertensive trials. Can J Psychiatry 1990 Apr; 35(3): 257–9PubMed
5.
go back to reference Biriell C, McEwen J, Sanz E. Depression associated with diltiazem (letter). BMJ 1989; 299(6702): 796PubMedCrossRef Biriell C, McEwen J, Sanz E. Depression associated with diltiazem (letter). BMJ 1989; 299(6702): 796PubMedCrossRef
6.
go back to reference Patten SB, Williams JV, Love EJ. Case-control studies of cardiovascular medications as risk factors for clinically diagnosed depressive disorders in a hospitalized population. Can J Psychiatry 1996 Sep; 41(7): 469–76PubMed Patten SB, Williams JV, Love EJ. Case-control studies of cardiovascular medications as risk factors for clinically diagnosed depressive disorders in a hospitalized population. Can J Psychiatry 1996 Sep; 41(7): 469–76PubMed
7.
go back to reference Dunn NR, Freemantle SN, Mann RD. Cohort study on calcium channel blockers, other cardiovascular agents, and the prevalence of depression. Br J Clin Pharmacol 1999 Aug; 48(2): 230–3PubMedCrossRef Dunn NR, Freemantle SN, Mann RD. Cohort study on calcium channel blockers, other cardiovascular agents, and the prevalence of depression. Br J Clin Pharmacol 1999 Aug; 48(2): 230–3PubMedCrossRef
8.
go back to reference Lindberg G, Bingefors K, Ranstam J, et al. Use of calcium channel blockers and risk of suicide: ecological findings confirmed in population based cohort study. BMJ 1998 Mar 7; 316(7133): 741–5PubMedCrossRef Lindberg G, Bingefors K, Ranstam J, et al. Use of calcium channel blockers and risk of suicide: ecological findings confirmed in population based cohort study. BMJ 1998 Mar 7; 316(7133): 741–5PubMedCrossRef
9.
go back to reference Sørensen HT, Mellemkj≸r L, Olsen JH. Risk of suicide in users of beta-adrenoceptor blockers, calcium channel blockers and angiotensin converting enzyme inhibitors. Br J Clin Pharmacol 2001 Sep; 52(3): 313–8PubMedCrossRef Sørensen HT, Mellemkj≸r L, Olsen JH. Risk of suicide in users of beta-adrenoceptor blockers, calcium channel blockers and angiotensin converting enzyme inhibitors. Br J Clin Pharmacol 2001 Sep; 52(3): 313–8PubMedCrossRef
10.
go back to reference Hullett FJ, Potkin SG, Levy AB, et al. Depression associated with nifedipine-induced calcium channel blockade. Am J Psychiatry 1988 Oct; 145(10): 1277–9PubMed Hullett FJ, Potkin SG, Levy AB, et al. Depression associated with nifedipine-induced calcium channel blockade. Am J Psychiatry 1988 Oct; 145(10): 1277–9PubMed
11.
go back to reference Dassylva B. Verapamil may cause depression. Can J Psychiatry 1993 May; 38(4): 299–300PubMed Dassylva B. Verapamil may cause depression. Can J Psychiatry 1993 May; 38(4): 299–300PubMed
12.
go back to reference McAllister-Williams RH. Calcium-channel blockade and depressive illness. Br J Psychiatry 1990 Oct; 157: 618–9PubMedCrossRef McAllister-Williams RH. Calcium-channel blockade and depressive illness. Br J Psychiatry 1990 Oct; 157: 618–9PubMedCrossRef
13.
go back to reference bergman U, Isacsson G. Use of calcium channel blockers and risk of suicide: independent studies are needed before causality is established (letter). BMJ 1998; 317(7165): 1076PubMedCrossRef bergman U, Isacsson G. Use of calcium channel blockers and risk of suicide: independent studies are needed before causality is established (letter). BMJ 1998; 317(7165): 1076PubMedCrossRef
14.
go back to reference Wiholm BE, Sundstrom A, Alfredsson L. Use of calcium channel blockers and risk of suicide: drug prescriptions over longer period should have been followed up. BMJ 1998 Oct 17; 317(7165): 1076–7PubMedCrossRef Wiholm BE, Sundstrom A, Alfredsson L. Use of calcium channel blockers and risk of suicide: drug prescriptions over longer period should have been followed up. BMJ 1998 Oct 17; 317(7165): 1076–7PubMedCrossRef
15.
go back to reference Chen YT, Makuch RW. Use of calcium channel blockers and risk of suicide: prescriptions for particular drug are influenced by numerous factors (letter). BMJ 1998; 317(7165): 1077PubMedCrossRef Chen YT, Makuch RW. Use of calcium channel blockers and risk of suicide: prescriptions for particular drug are influenced by numerous factors (letter). BMJ 1998; 317(7165): 1077PubMedCrossRef
16.
go back to reference Gasse C, Derby LE, Vasilakis C, et al. Risk of suicide among users of calcium channel blockers: population based, nested case-control study (short report). BMJ 2000; 320(7244): 1251PubMedCrossRef Gasse C, Derby LE, Vasilakis C, et al. Risk of suicide among users of calcium channel blockers: population based, nested case-control study (short report). BMJ 2000; 320(7244): 1251PubMedCrossRef
17.
go back to reference Fletcher RH, Fletcher SW, Wagner EH. Clinical epidemiology: the essentials. 3rd ed. Baltimore: Williams & Wilkins, 1996 Fletcher RH, Fletcher SW, Wagner EH. Clinical epidemiology: the essentials. 3rd ed. Baltimore: Williams & Wilkins, 1996
18.
go back to reference Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia (PA): Lippincott Williams & Wilkins, 1998 Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia (PA): Lippincott Williams & Wilkins, 1998
19.
go back to reference Olsen JH, Sørensen HT, Friis S, et al. Cancer risk in users of calcium channel blockers. Hypertension 1997 May; 29(5): 1091–4PubMedCrossRef Olsen JH, Sørensen HT, Friis S, et al. Cancer risk in users of calcium channel blockers. Hypertension 1997 May; 29(5): 1091–4PubMedCrossRef
20.
go back to reference Stanton AV. Calcium channel blockers: the jury is still out on whether they cause heart attacks and suicide. BMJ 1998 May 16; 316(7143): 1471–3PubMedCrossRef Stanton AV. Calcium channel blockers: the jury is still out on whether they cause heart attacks and suicide. BMJ 1998 May 16; 316(7143): 1471–3PubMedCrossRef
21.
go back to reference Ried LD, McFarland BH, Johnson RE, et al. Beta-blockers and depression: the more the murkier? Ann Pharmacother 1998 Jun; 32(6): 699–708PubMedCrossRef Ried LD, McFarland BH, Johnson RE, et al. Beta-blockers and depression: the more the murkier? Ann Pharmacother 1998 Jun; 32(6): 699–708PubMedCrossRef
22.
go back to reference Den Almindelige Danske Lægeforening. Lægeforeningens Medicinfortegnelse. 24th ed. Copenhagen: Lægeforeningens Forlag, 2001 Den Almindelige Danske Lægeforening. Lægeforeningens Medicinfortegnelse. 24th ed. Copenhagen: Lægeforeningens Forlag, 2001
23.
go back to reference Kyvik KO, Stenager EN, Green A, et al. Suicides in men with IDDM. Diabetes Care 1994 Mar; 17(3): 210–2PubMedCrossRef Kyvik KO, Stenager EN, Green A, et al. Suicides in men with IDDM. Diabetes Care 1994 Mar; 17(3): 210–2PubMedCrossRef
24.
go back to reference Lindberg G, Ranstam J, Melander A, et al. Authors reply (letter). BMJ 1998; 317(7165): 1077CrossRef Lindberg G, Ranstam J, Melander A, et al. Authors reply (letter). BMJ 1998; 317(7165): 1077CrossRef
26.
go back to reference Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the scale for suicide ideation. J Consult Clin Psychol 1979 Apr; 47(2): 343–52PubMedCrossRef Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the scale for suicide ideation. J Consult Clin Psychol 1979 Apr; 47(2): 343–52PubMedCrossRef
27.
go back to reference PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998 Nov 7; 352(9139): 1498–504CrossRef PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998 Nov 7; 352(9139): 1498–504CrossRef
28.
go back to reference Conant J, Engler R, Janowsky D, et al. Central nervous system side effects of beta-adrenergic blocking agents with high and low lipid solubility. J Cardiovasc Pharmacol 1989 Apr; 13(4): 656–61PubMed Conant J, Engler R, Janowsky D, et al. Central nervous system side effects of beta-adrenergic blocking agents with high and low lipid solubility. J Cardiovasc Pharmacol 1989 Apr; 13(4): 656–61PubMed
29.
go back to reference Opie LH. Angiotensin-converting enzyme inhibitors: the advance continues. 3rd ed. New York: Authors’ Publishing House, 1999 Opie LH. Angiotensin-converting enzyme inhibitors: the advance continues. 3rd ed. New York: Authors’ Publishing House, 1999
30.
go back to reference Pucilowski O. Psychopharmacological properties of calcium channel inhibitors. Psychopharmacology (Berl) 1992; 109(1–2): 12–29CrossRef Pucilowski O. Psychopharmacological properties of calcium channel inhibitors. Psychopharmacology (Berl) 1992; 109(1–2): 12–29CrossRef
Metadata
Title
Risk of Suicide in Users of Cardiovascular Drugs
A Review of the Epidemiological Evidence
Authors
Dr Peter Jepsen
Søren P. Johnsen
Henrik T. Sørensen
Publication date
01-05-2003
Publisher
Springer International Publishing
Published in
American Journal of Cardiovascular Drugs / Issue 3/2003
Print ISSN: 1175-3277
Electronic ISSN: 1179-187X
DOI
https://doi.org/10.2165/00129784-200303030-00002

Other articles of this Issue 3/2003

American Journal of Cardiovascular Drugs 3/2003 Go to the issue

Adis Drug Evaluation

The Sirolimus-Eluting Stent

Review Article

New Anticoagulants